Manufacturers: LongBio Pharma
LP-005 is a first-in-class bi-functional complement antibody-fusion protein targeting both C5 and C3b, developed by LongBio Pharma. It has leading potential globally and shows therapeutic potential compared with single-target complement inhibitors.
LP-005 is a first-in-class bi-functional complement antibody-fusion protein targeting both C5 and C3b, developed by LongBio Pharma. It has leading potential globally and shows therapeutic potential compared with single-target complement inhibitors.
LP-005 is a bi-functional complement antibody-fusion protein that targets both C5 and C3b, offering a dual-target mechanism that shows therapeutic potential compared with single-target complement inhibitors.
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
